
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to experience growth in GAAP earnings per diluted share, with expectations of $4.73 for 2025 and $5.17 for 2026, reflecting a positive trajectory in financial performance. The company anticipates continued strength in its Human Nutrition and Health segment, contributing to sequential growth and improved gross and net margins moving forward, alongside a potential debt-free status by the end of the year. Furthermore, Balchem's revenue trajectory shows promising increases, with a reported sales growth of 9.8% year-over-year and operational efficiency enhancing performance metrics.
Bears say
Balchem Corp's forecast for 2026 projects earnings of $5.10 per diluted share, a slight decline from the previous estimate of $5.17, contributing to a decrease in the price-to-earnings multiple from 39.6x to 37.9x. The company's Human Nutrition and Health and Animal Nutrition and Health segments reported revenues of $166.1 million and $56.4 million for 4Q25 and 3Q25, respectively, both of which fell short of forecasts. Risks such as slower growth in core businesses, inflationary pressures, potential product launch failures, and geopolitical disruptions create a challenging environment for Balchem, which may limit its financial performance moving forward.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares